Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAP-486 dose-ranging study in acute coronary syndrome with nonsustained ventricular tachycardia
2005-000671-17Phase 2Terminated
- Sponsor
- Wyeth
- Start
- May 2005
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2 trial of rotigaptide in acute coronary syndrome (ACS), ventricular tachycardia (VT) and cardiac ischemia, sponsored by Wyeth. Primary endpoint: Total number of ventricular arrhythmia beats during the 24-hour on-therapy phase. Started May 2005; status: terminated.
02
Drugs
rotigaptide
03
Conditions
acute coronary syndrome (ACS)ventricular tachycardia (VT)cardiac ischemia
Beyond the preview
Go deeper on 2005-000671-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000671-17.